The annual meeting vote on October 1 is a binary event for AEMD's capital structure. If all proposals pass, the company gains authority to issue up to 200M common shares and 20M preferred shares, likely leading to severe dilution. Traders should monitor proxy voting trends and consider short positioning if proposals appear likely to pass. The stock may face continued downward pressure from the overhang of potential issuance.
Price Chart
Executive Summary
Aethlon Medical filed a DEFA14A supplement correcting scrivener's errors on the proxy card for its October 1, 2026 annual meeting. The underlying proxy contains 10 proposals including a 10x increase in authorized common shares (20M to 200M), authorization of 20M preferred shares, and approval of warrant exercises and future dilutive financings. This is a routine administrative correction, but the proposals themselves represent massive potential dilution for a $3M market cap company.
Key Financial Metrics
Key Facts
- Annual meeting scheduled for October 1, 2026 at 8:00 a.m. PT
- Proposal 6 seeks to increase authorized common shares from 20,000,000 to 200,000,000 (10x)
- Proposal 7 seeks to authorize 20,000,000 shares of preferred stock
- Proposal 3 seeks approval of shares issuable upon exercise of warrants from July 2026 offering
- Proposal 5 seeks to increase 2020 Equity Incentive Plan by 100,000 shares
- Proposals 8 and 9 seek approval for future private financings and warrant inducement transactions
- Board recommends FOR all proposals; proxies will be voted FOR if no specification made
- Company market cap is approximately $3M
Financial Impact
Authorized common shares would increase 10x from 20M to 200M, plus 20M preferred shares authorized, enabling massive future dilution. Current market cap ~$3M.
Risk Factors
- Massive dilution if authorized share increase and preferred stock authorization are approved
- Potential Nasdaq delisting risk given micro-cap status and need for dilutive financing
- Warrant exercises and future financings could further depress share price
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 8 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| DEFA14A Filing (AEMD) — Batch item 1 | 0001683168-26-006969 |
| Document: 0001683168-26-006969-index-headers.html | 0001683168-26-006969 |
| Document: 0001683168-26-006969-index.html | 0001683168-26-006969 |
| Document: 0001683168-26-006969.txt | 0001683168-26-006969 |
| DEFA14A Filing (AEMD) — Batch item 5 | 0001683168-26-006969 |
| Document: 0001683168-26-006969-index-headers.html | 0001683168-26-006969 |
| Document: 0001683168-26-006969-index.html | 0001683168-26-006969 |
| Document: 0001683168-26-006969.txt | 0001683168-26-006969 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 13, 2026 12d ago | SC 13G | $5.05 $5.07 | ▲ +0.40% | ▼ −0.06% | $5.01 (−0.75%) |
Oct 1, 2026 24d ago | 8-K | $6.45 $6.05 | ▲ +6.20% | ▲ +7.36% | $5.01 (+22.29%) |
Sep 17, 2026 5w ago | 425 | $6.78 $6.77 | ▼ −0.15% | ▼ −0.75% | $5.01 (−26.08%) |
Sep 17, 2026 5w ago | 8-K | $6.78 $6.77 | ▼ −0.15% | ▼ −0.75% | $5.01 (−26.08%) |
Sep 15, 2026 5w ago | 8-K | $1.47 $6.31 | ▲ +329.25% | ▲ +328.43% | $5.01 (+240.96%) |
Sep 4, 2026 7w ago | DEFA14A | $1.81 $1.47 | ▲ +18.78% | ▲ +17.67% | $5.01 (−176.91%) |
Aug 31, 2026 8w ago | 8-K | $2.06 $1.81 | ▼ −12.14% | ▼ −11.99% | $5.01 (+143.31%) |
Aug 13, 2026 10w ago | Press Release | $2.83 $2.73 | ▼ −3.53% | ▼ −2.17% | $5.01 (+77.11%) |
Jul 31, 2026 12w ago | 8-K | $0.6628 $0.6300 | ▲ +4.95% | ▲ +8.46% | $5.01 (−656.20%) |
Jul 7, 2026 15w ago | EFFECT | $0.7297 $0.6850 | ▲ +6.13% | ▲ +6.68% | $5.01 (−586.87%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers